Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 52B (TMEM52B)
- Target
- TMEM52B
- Molecular classification
- Transmembrane protein, Single-pass type I membrane protein, Other
01
Overview
Transmembrane protein 52B (TMEM52B) is a single-pass type I membrane protein, mainly located in the plasma membrane and extracellular exosomes. This protein is widely expressed in normal human tissues, with high levels in the kidney. TMEM52B plays a key role in modulating E-cadherin stability and cell–cell adhesion, supporting epithelial integrity. Experimental and clinical data indicate TMEM52B functions as a tumor suppressor, where decreased TMEM52B expression correlates with increased tumor invasion, enhanced signaling of downstream effectors such as β-catenin and EGFR, and poor clinical prognosis in cancers like colorectal and renal cell carcinoma. Research shows that TMEM52B-derived peptides can suppress cancer cell survival, anchorage-independent growth, and metastasis, highlighting its potential as both a therapeutic target and a prognostic biomarker in oncology.
- Other names
- C12orf59UNQ5927/PRO19821FLJ31166
02
Mechanism of action
In experimental models, TMEM52B-derived peptides inhibit tumor progression by stabilizing E-cadherin, reducing soluble E-cadherin, and interfering with EGFR activation
03
Biological functions
Modulation of E-cadherin stability and cell–cell adhesionInhibition of epithelial–mesenchymal transition (EMT)Suppression of cancer cell survival and invasionRegulation of EGFR and β-catenin signalingPotential tumor suppressor activity
04
Disease associations
Cancer (tumor suppressor in several cancers, including colon, kidney, lung, and breast cancer)
05
Safety considerations
None specifically reported in the current literature; ongoing research on peptide-based therapeutics targeting TMEM52B
06
Interacting drugs
None currently approved; TMEM52B-derived peptides are under investigation as therapeutic agents in cancer
07
Biomarkers
TMEM52B expression level is a potential prognostic biomarker in breast, lung, kidney, and rectal cancer
Beyond the preview
Go deeper on Transmembrane protein 52B (TMEM52B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane protein 52B (TMEM52B).